BNTX Valuation

Biontech SE

Add to Watchlist

Advanced Chart

88.050

-3.960(-4.300%)

Overview
Forecast
Valuation

BNTX Relative Valuation

BNTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BNTX is overvalued; if below, it's undervalued.

Historical Valuation

Biontech SE(BNTX) is now in theOvervaluedzone, suggesting that its currentforward PSratio of9.43is consideredOvervaluedcompared with the five-year average of5.78.The fair price of Biontech SE(BNTX)is between32.00to75.72according to relative valuation methord.Compared to the current price of88.05USD, Biontech SE isOvervalued By 16.28%.

Relative Value

Fair Zone

32.00-75.72

Current Price：88.05

16.28%

Overvalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

0.99

P/B

Median3y

1.43

Median5y

6.78

-0.39

FCF Yield

Median3y

23.75

Median5y

14.11

Competitors Valuation Multiple

The average P/S ratio for BNTX's competitors is 4.96, providing a benchmark for relative valuation. Biontech SE Corp (BNTX) exhibits a P/S ratio of 9.43, which is 90.24% above the industry average. Given its robust revenue growth of -19.54%, this premium appearsunsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap